"Number of ADSs outstanding on a fully diluted basis as of June 30, 2021 was 12,584,362 (or 251,687,240 ordinary shares) which includes 699,806 ADSs (or 13,996,120 ordinary shares) sold during the quarter ended June 30, 2021 under the Company's ATM program"
https://finance.yahoo.com/news/chemomab-therapeutics-announces-second-quarter-120000199.html

Liked By
Spread the love. Be the first to like this post!
Recent CMMB News
- Current Report Filing (8-k) • Edgar (US Regulatory) • 01/11/2023 09:02:47 PM
- Statement of Changes in Beneficial Ownership (4) • Edgar (US Regulatory) • 01/05/2023 09:50:08 PM
- Statement of Changes in Beneficial Ownership (4) • Edgar (US Regulatory) • 01/05/2023 09:02:30 PM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 01/03/2023 12:06:21 PM
- Chemomab Reports Top-Line Results from CM-101 Phase 2a Liver Fibrosis Biomarker Trial in NASH Patients • PR Newswire (US) • 01/03/2023 12:00:00 PM
- Chemomab Reports Independent Drug Monitoring Committee Safety Review of CM-101 Phase 2 Trial in Primary Sclerosing Cholangitis • PR Newswire (US) • 12/21/2022 12:00:00 PM
- Chemomab Announces Appointment of Mitchell L. Jones, MD, PhD as Vice President of Corporate Development & Strategy • PR Newswire (US) • 11/30/2022 12:00:00 PM
- Statement of Changes in Beneficial Ownership (4) • Edgar (US Regulatory) • 11/18/2022 12:54:00 PM
- Statement of Changes in Beneficial Ownership (4) • Edgar (US Regulatory) • 11/17/2022 09:57:27 PM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 11/16/2022 12:21:40 PM
- Initial Statement of Beneficial Ownership (3) • Edgar (US Regulatory) • 11/15/2022 09:04:26 PM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 11/14/2022 09:11:05 PM
- Chemomab Therapeutics Announces Third Quarter 2022 Financial Results and Provides Corporate Update • PR Newswire (US) • 11/11/2022 11:00:00 AM
- Quarterly Report (10-q) • Edgar (US Regulatory) • 11/10/2022 09:13:07 PM
- Chemomab Presents Clinical Data from Investigator-Initiated Study Showing CM-101 Reduced Inflammatory and Fibrogenesis-Related Biomarkers in Patients with Severe Lung Injury Derived from Covid-19 • PR Newswire (US) • 11/09/2022 01:00:00 PM
- Chemomab Therapeutics to Report Third Quarter 2022 Financial Results and Provide a Business Update • PR Newswire (US) • 11/01/2022 11:00:00 AM
- Chemomab Therapeutics to Present at Upcoming Scientific Conferences • PR Newswire (US) • 10/28/2022 11:00:00 AM
- Securities Registration: Employee Benefit Plan (s-8) • Edgar (US Regulatory) • 08/15/2022 08:07:34 PM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 08/12/2022 11:08:54 AM
- Chemomab Adds Highly Experienced Executives Further Strengthening Its R&D and Clinical Capabilities • PR Newswire (US) • 08/12/2022 10:00:00 AM
- Chemomab Therapeutics Announces Second Quarter 2022 Financial Results and Provides Corporate Update • PR Newswire (US) • 08/12/2022 10:00:00 AM
- Chemomab Therapeutics to Report Second Quarter 2022 Financial Results and Provide a Business Update • PR Newswire (US) • 08/01/2022 11:00:00 AM
- Chemomab Presents Data Further Supporting the Mechanism of Action and Potential Efficacy of CM-101 in Primary Sclerosing Cholangitis • PR Newswire (US) • 06/27/2022 12:00:00 PM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 06/21/2022 11:01:09 AM
- Chemomab Therapeutics Appoints Jill M. Quigley, JD, to Its Board of Directors • PR Newswire (US) • 06/21/2022 11:00:00 AM
FEATURED 1606 Corp Now Trading under Ticker CBDW, Management Announces First Acquisition • Jan 27, 2023 11:59 AM
IQST - iQSTEL Reminds Shareholders To Get Their Votes In Before Annual Meeting Next Week On January 31, 2023 • IQST • Jan 26, 2023 9:53 AM
Nextech AR's AI-Powered CAD to Poly Toggle3D Launches Major Technology Advancements • ARWYF • Jan 26, 2023 8:46 AM
UCASU jump-starts its plan of NASDAQ or NYSE up-listing in 2023 • UCASU • Jan 26, 2023 7:21 AM
Kaya Holdings, Inc. (OTCQB: KAYS) Launches Fifth Dimension Therapeutics™ to seek to Provide Innovative Psychedelic-Based Treatments for Depression and Anxiety Related Conditions and Address the Growing Multi-Billion Dollar Global Psychedelics Market • KAYS • Jan 25, 2023 10:53 AM
B2 Digital's B2 SPORTS NETWORK (B2SN) Expands Distribution to Europe, Russia, and Asia with StayLIVE Agreement • BTDG • Jan 25, 2023 10:00 AM